CN106604932B - 人白细胞介素-2的免疫刺激单克隆抗体 - Google Patents

人白细胞介素-2的免疫刺激单克隆抗体 Download PDF

Info

Publication number
CN106604932B
CN106604932B CN201580048027.0A CN201580048027A CN106604932B CN 106604932 B CN106604932 B CN 106604932B CN 201580048027 A CN201580048027 A CN 201580048027A CN 106604932 B CN106604932 B CN 106604932B
Authority
CN
China
Prior art keywords
hil
binding
antibody
antigen
mab
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580048027.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN106604932A (zh
Inventor
奥努尔·波伊曼
娜塔莉亚·阿瑞纳斯拉米雷斯
邹超
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zurich Universitaet Institut fuer Medizinische Virologie
Original Assignee
Zurich Universitaet Institut fuer Medizinische Virologie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zurich Universitaet Institut fuer Medizinische Virologie filed Critical Zurich Universitaet Institut fuer Medizinische Virologie
Publication of CN106604932A publication Critical patent/CN106604932A/zh
Application granted granted Critical
Publication of CN106604932B publication Critical patent/CN106604932B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/246—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201580048027.0A 2014-07-10 2015-07-10 人白细胞介素-2的免疫刺激单克隆抗体 Active CN106604932B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14176619 2014-07-10
EP14176619.6 2014-07-10
PCT/IB2015/055226 WO2016005950A1 (en) 2014-07-10 2015-07-10 Immune-stimulating monoclonal antibodies against human interleukin-2

Publications (2)

Publication Number Publication Date
CN106604932A CN106604932A (zh) 2017-04-26
CN106604932B true CN106604932B (zh) 2024-12-10

Family

ID=51162588

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580048027.0A Active CN106604932B (zh) 2014-07-10 2015-07-10 人白细胞介素-2的免疫刺激单克隆抗体

Country Status (9)

Country Link
US (2) US10894828B2 (enExample)
EP (2) EP3166973B1 (enExample)
JP (1) JP7209464B2 (enExample)
CN (1) CN106604932B (enExample)
AU (1) AU2015287227B2 (enExample)
CA (1) CA2954476C (enExample)
DK (1) DK3166973T3 (enExample)
ES (2) ES2989669T3 (enExample)
WO (1) WO2016005950A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018014150A2 (en) * 2016-01-11 2018-12-11 Novartis Ag immunostimulating humanized monoclonal antibodies to human interleukin-2, and fusion proteins thereof
AU2017335771A1 (en) 2016-09-28 2019-02-28 Musc Foundation For Research Development Antibodies that bind interleukin-2 and uses thereof
GB201621806D0 (en) * 2016-12-21 2017-02-01 Philogen Spa Immunocytokines with progressive activation mechanism
CN110913873A (zh) * 2017-02-23 2020-03-24 希望之城 用于cd8+t细胞的体内扩增并预防或治疗gvhd的方法
EP3600421A4 (en) * 2017-03-23 2021-01-06 The Trustees of The University of Pennsylvania ANTI-C5A ANTIBODIES AND USES OF THEM
JP7057980B2 (ja) * 2017-05-25 2022-04-21 インスティテュート フォー ベーシック サイエンス 抗－ヒトインターロイキン－２抗体及びその用途
US12454561B2 (en) 2018-03-19 2025-10-28 Multivir Inc. Methods and compositions comprising tumor suppressor gene therapy and CD122/CD132 agonists for the treatment of cancer
WO2021113644A1 (en) 2019-12-05 2021-06-10 Multivir Inc. Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
EP4090377A1 (en) 2020-01-13 2022-11-23 Synaffix B.V. Conjugates of antibodies an immune cell engagers
CN115397852B (zh) 2020-02-16 2023-08-11 奥罗斯生物科学公司 工程化抗il-2抗体
IL297329A (en) * 2020-04-22 2022-12-01 Merck Sharp & Dohme Llc Dimeric interleukin-2 beta gamma receptor-biased human interleukin-2 conjugates conjugated to soluble non-peptide polymers.
KR20230048151A (ko) * 2020-08-18 2023-04-10 유니버시타트 취리히 Cd25 편향된 항-il-2 항체
JP2024506022A (ja) 2021-02-08 2024-02-08 シンアフィックス ビー．ブイ． 多機能性抗体
JP2024539749A (ja) 2021-10-14 2024-10-29 ラッティコン （スージョウ） バイオファーマシューティカルズ カンパニー リミテッド 新規な抗体－サイトカイン融合タンパク質及びその製造方法と使用
US11773160B1 (en) 2022-08-05 2023-10-03 Anaveon AG Immune-stimulating IL-2 fusion proteins
CN119912559B (zh) * 2025-01-22 2025-12-26 贵州中医药大学 一种新冠病毒变异株jn.1刺突s蛋白的单链抗体及其应用
CN119775409B (zh) * 2025-03-05 2025-07-11 深圳真实生物医药科技有限公司 靶向sost的抗体及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101045923A (zh) * 2006-03-31 2007-10-03 沈阳三生制药有限责任公司 生产一种白细胞介素类似物的方法
CN101189265A (zh) * 2005-06-01 2008-05-28 米克罗麦特股份公司 抗il2抗体

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK174501B1 (da) 1983-12-23 2003-04-28 Hoffmann La Roche Fremgangsmåde til fremstilling af interleukin-2
JPS62269698A (ja) * 1986-03-17 1987-11-24 エフ．ホフマン　―　ラ　ロシュ　アーゲー Ｉｌ−２蛋白質に対するモノクロ−ナル抗体
US6111090A (en) 1996-08-16 2000-08-29 Schering Corporation Mammalian cell surface antigens; related reagents
WO1998006842A1 (en) 1996-08-16 1998-02-19 Schering Corporation Mammalian cell surface antigens; related reagents
WO1998056915A2 (en) 1997-06-12 1998-12-17 Research Corporation Technologies, Inc. Artificial antibody polypeptides
JP2006512391A (ja) 2002-12-30 2006-04-13 スリーエム イノベイティブ プロパティズ カンパニー 組み合わせ免疫賦活薬
EP1765402A2 (en) 2004-06-04 2007-03-28 Duke University Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity
CN102875681A (zh) 2005-07-08 2013-01-16 拜奥根Idec马萨诸塞公司 抗-αvβ6抗体及其用途
US20100310501A1 (en) * 2006-02-16 2010-12-09 Onur Boyman Methods for Improving Immune Function and Methods for Prevention or Treatment of Disease in a Mammalian Subject
EP2242773B1 (en) 2008-02-11 2017-06-14 Cure Tech Ltd. Monoclonal antibodies for tumor treatment
LT3339323T (lt) 2010-08-12 2020-02-10 Eli Lilly And Company Amiloido beta peptido antikūnai prieš n3glu ir jų panaudojimas
US9266938B2 (en) 2011-02-10 2016-02-23 Roche Glycart Ag Mutant interleukin-2 polypeptides
WO2013157105A1 (ja) 2012-04-18 2013-10-24 公立大学法人大阪市立大学 ムチンサブタイプ５ａｃ特異的ヒト化抗体およびその利用
CN112587671A (zh) 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
WO2015109212A1 (en) * 2014-01-17 2015-07-23 Pfizer Inc. Anti-il-2 antibodies and compositions and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101189265A (zh) * 2005-06-01 2008-05-28 米克罗麦特股份公司 抗il2抗体
CN101045923A (zh) * 2006-03-31 2007-10-03 沈阳三生制药有限责任公司 生产一种白细胞介素类似物的方法

Also Published As

Publication number Publication date
CN106604932A (zh) 2017-04-26
CA2954476C (en) 2023-09-19
JP2017525343A (ja) 2017-09-07
US10894828B2 (en) 2021-01-19
CA2954476A1 (en) 2016-01-14
US20210230269A1 (en) 2021-07-29
EP3693389B1 (en) 2024-09-04
EP3693389A1 (en) 2020-08-12
WO2016005950A1 (en) 2016-01-14
EP3166973A1 (en) 2017-05-17
AU2015287227A1 (en) 2017-02-09
ES2989669T3 (es) 2024-11-27
AU2015287227B2 (en) 2021-02-18
EP3693389C0 (en) 2024-09-04
EP3166973B1 (en) 2020-02-19
ES2779977T3 (es) 2020-08-21
DK3166973T3 (da) 2020-04-06
JP7209464B2 (ja) 2023-01-20
EP3693389A9 (en) 2021-04-07
US20170183403A1 (en) 2017-06-29
AU2015287227A8 (en) 2017-02-16

Similar Documents

Publication Publication Date Title
CN106604932B (zh) 人白细胞介素-2的免疫刺激单克隆抗体
JP7562528B2 (ja) 抗体及びその用途
CN112955471B (zh) Cd3抗体及其药物用途
KR102662387B1 (ko) B7-h3 항체, 이의 항원-결합 단편 및 이의 의학적 용도
CN112969476B (zh) 多特异性蛋白分子
CN111744013A (zh) 抗tigit抗体联合pd-1抑制剂治疗疾病的方法和药物组合
CN114502591A (zh) 靶向bcma的抗体、双特异性抗体及其用途
CN112646032A (zh) 靶向bcma的具有人猴交叉的人源化单克隆抗体
CN113227148B (zh) 抗gpc3抗体、其抗原结合片段及其医药用途
WO2023125888A1 (zh) 一种gprc5d抗体及其应用
CN110642951A (zh) 一种抗ca125糖类抗原的高中和活性纳米抗体及其应用
CN117279950A (zh) 一种靶向il-18bp的抗体及其应用
CN116554323B (zh) 人源化抗il21抗体的开发和应用
CN115298216A (zh) 抗体或其抗原结合片段、其制备方法及医药用途
WO2024017326A1 (zh) 抗gprc5d纳米抗体及其应用
CN111788229A (zh) Csf1r结合剂
WO2024234019A2 (en) Trop2 antibodies
CN120603848A (zh) 三特异性抗原结合分子及其应用
WO2023186100A1 (zh) 抗ror1的抗体及其用途
CN115124620B (zh) 一种能够激活nk细胞的抗体及其应用
JP6996825B2 (ja) 修飾ＣκおよびＣＨ１ドメイン
CN118355032A (zh) Bcma抗体及其应用
WO2025146128A1 (zh) 抗liv-1的抗体及其用途
HK40051452A (en) Cd3 antibody and pharmaceutical use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20200323

Address after: 71 laimi street, Zurich, ch-8006, Switzerland

Applicant after: UNIVERSITAT ZURICH

Address before: 35 Richter street, Basel, Switzerland

Applicant before: Novartis AG

Applicant before: UNIVERSITAT ZURICH

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant